Valuation: CSL Limited

Market Cap 39.12B 34.35B 31.62B 29.46B 55.56B 3,719B 56.69B 380B 147B 1,826B 147B 144B 6,354B P/E 2026 *
-44x
P/E 2027 * 27.2x
Enterprise Value 47.97B 42.12B 38.77B 36.12B 68.13B 4,561B 69.51B 466B 181B 2,239B 180B 176B 7,791B EV / Sales 2026 *
3.12x
EV / Sales 2027 * 3.02x
Free-Float
99.3%
Yield 2026 *
3.49%
Yield 2027 * 3.58%
1 day-0.52%
1 week+0.08%
Current month+2.62%
1 month+27.21%
3 months-15.25%
6 months-31.52%
Current year-31.80%
1 week 112.4
Extreme 112.4
118.6
1 month 90
Extreme 90
118.88
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
275.79
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 10/02/2026
Director of Finance/CFO 52 06/10/2025
Chief Tech/Sci/R&D Officer 64 30/09/2020
Director TitleAgeSince
Director/Board Member 72 16/10/2018
Director/Board Member 70 13/08/2013
Director/Board Member 68 15/02/2016
Date Insider Type Main position Quantity % Market Cap.
05-31Buy

Director

1,036 0.0002%
05-25Buy

Chief Executive Officer

1,100 0.0002%
05-25Buy

Chief Executive Officer

1,100 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-0.52%+0.08%-50.89%-57.38% 39.12B
+0.19%+0.21%+16.79%-13.06% 63.56B
+0.54%+1.05%+55.55%+226.08% 55.92B
+0.36%+39.60%+39.60%+39.60% 41.68B
-2.93%+5.09%+61.25%-26.37% 30.97B
+3.53%+19.99%+152.70%-40.33% 28.77B
+0.40%+4.93%+65.59%+82.83% 22.74B
+7.22%+12.16%+7.63%+184.50% 17.64B
-0.11%-0.60%+63.70%+124.40% 16.66B
+0.05%+7.44%+74.19%+333.26% 14.6B
Average +0.87%+4.95%+48.61%+85.35% 33.16B
Weighted average by Cap. +0.55%+3.98%+41.89%+64.27%

Financials

2026 *2027 *
Net sales 15.39B 13.51B 12.44B 11.59B 21.86B 1,463B 22.3B 150B 57.97B 718B 57.79B 56.54B 2,500B 15.64B 13.73B 12.64B 11.77B 22.21B 1,486B 22.66B 152B 58.88B 730B 58.71B 57.44B 2,539B
Net income -894M -785M -722M -673M -1.27B -84.95B -1.29B -8.69B -3.37B -41.7B -3.36B -3.28B -145B 1.18B 1.04B 956M 891M 1.68B 112B 1.71B 11.5B 4.46B 55.22B 4.44B 4.35B 192B
Net Debt 8.85B 7.77B 7.15B 6.66B 12.57B 841B 12.82B 86.02B 33.33B 413B 33.23B 32.51B 1,437B 8.07B 7.09B 6.52B 6.08B 11.46B 767B 11.69B 78.44B 30.39B 377B 30.3B 29.65B 1,311B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,904
Date Price Change Volume
02/07/26 A$117.75 -0.52% 1,298,766
01/07/26 A$118.37 +3.16% 1,537,670
30/06/26 A$114.74 -0.56% 1,606,736
29/06/26 A$115.39 +0.45% 1,458,143
26/06/26 A$114.87 -2.36% 2,308,629
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
81.69USD
Average target price
96.61USD
Spread / Average Target
+18.27%

Quarterly revenue - Rate of surprise